We need a drug that is easier to use. It is Methylene Blue. This old molecule, dates from 1876. Methylene Blue has many effects; among others is the revival of the mitochondria.

Montégut, L., Martínez-Basilio, P. C., da Veiga Moreira, J., Schwartz, L., Jolicoeur, M. (2020). Combining lipoic acid to methylene blue reduces the Warburg effect in CHO cells: From TCA cycle activation to enhancing monoclonal antibody production. Plos one, 15(4), e0231770.


In Europe, a physician can prescribe Methylene Blue. The pharmacist will have to put the drug into pills to be taken by patients. No pharmaceutical company sells ready to use capsules. There is also over-the-counter Methylene Blue on the Internet. It is mainly used in aquaculture to limit fish infections.

Methylene blue is a synthetic chemical compound. Like all drugs, it has side effects. It is excreted intact by the kidney and stains the urine dark blue. Methylene Blue can also cause a feeling of intense need to urinate, despite an almost empty bladder. Its main side effect is cerebral. Patients portray a well-being feeling. Most antidepressants are chemically derivatives of Methylene Blue. It should therefore not be combined with another antidepressant. Stopping must be gradual.

Within the narrow framework of the legislation, we could not make the therapeutic tests that must be carried out. Despite hundreds of corroborating publications, the absence of toxicity and the low cost of the molecules, we have not yet been able to convince the decision makers. The recent creation of the Foundation “Guérir du Cancer” under the aegis of the Fondation de France may allow this clinical work to begin.

First, this treatment is not sufficient for the most aggressive cancers, such as those, which no longer respond to different lines of chemotherapy. For example, this treatment is not effective for pancreatic cancers, which are even unresponsive to several cycles of chemotherapy. For these patients, we need a more powerful treatment to be developed in future.

For less aggressive cancers, this treatment seems to delay death. Glioblastomas are tumors that are usually fatal within a year. A metabolic treatment slows the evolution to the point where some have recommended it from start.

Seyfried, T. N., Shelton, L., Arismendi-Morillo, G., Kalamian, M., Elsakka, A., Maroon, J., Mukherjee, P. (2019). Provocative question: should ketogenic metabolic therapy become the standard of care for glioblastoma? Neurochemical research, 44(10), 2392-2404.